{"id":501548,"date":"2024-08-01T18:40:37","date_gmt":"2024-08-01T18:40:37","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/501548\/glaucoma-drugs-market-size-2034-allergan-sun-pharma-advanced-research-company-limited-santen-pharmaceutical-co-ltd-dwestern-therapeutics-institute-dwti-kowa-ltd-alcon.html"},"modified":"2024-08-01T18:40:37","modified_gmt":"2024-08-01T18:40:37","slug":"glaucoma-drugs-market-size-2034-allergan-sun-pharma-advanced-research-company-limited-santen-pharmaceutical-co-ltd-dwestern-therapeutics-institute-dwti-kowa-ltd-alcon","status":"publish","type":"post","link":"https:\/\/www.oklahomanews-online.com\/news\/story\/501548\/glaucoma-drugs-market-size-2034-allergan-sun-pharma-advanced-research-company-limited-santen-pharmaceutical-co-ltd-dwestern-therapeutics-institute-dwti-kowa-ltd-alcon.html","title":{"rendered":"Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/uploads\/1722520042.jpeg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon\" src=\"https:\/\/www.abnewswire.com\/uploads\/1722520042.jpeg\" alt=\"Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s&nbsp;<strong>&ldquo;Glaucoma Market Insights, Epidemiology and Market Forecast &ndash; 2034&rdquo;<\/strong>&nbsp;report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Explore the intricate details of the Glaucoma Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Glaucoma Market Forecast. Click here to stay ahead in healthcare innovation @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Glaucoma Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the Glaucoma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>The Glaucoma diagnosed prevalent cases were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.<\/li>\n<li>Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma.<\/li>\n<li>Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per DelveInsight&rsquo;s estimates, of all POAG cases in the 7MM, 52% were of NTG type.<\/li>\n<li>Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 701,946 cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.<\/li>\n<li>Japan accounted for 23% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.<\/li>\n<li>The leading Glaucoma Companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck &amp; Co, Aerie Pharmaceuticals, Ube Industries, and others.<\/li>\n<li>Promising Glaucoma Pipeline Therapies such as NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost\/ DE-126\/ ONO-9054\/ STN-1012600, Catioprost\/ DE-130A\/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Navigate the complexities of the Glaucoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Glaucoma Market Forecast. Click here to get more insights @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Glaucoma Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Glaucoma Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Total Glaucoma Prevalence Cases<\/li>\n<li>Prevalent Cases of Glaucoma by severity<\/li>\n<li>Glaucoma Gender-specific Prevalence Cases<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Glaucoma<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Delve deep into the Glaucoma Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Glaucoma Market Forecast. Click here to shape the future @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Glaucoma Prevalence<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Glaucoma Market Insights<\/strong><\/p>\n<p style=\"text-align: justify\">Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years. The damage caused by glaucoma cannot be reversed. But, treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery, or a combination.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Glaucoma Treatment Market Landscape<\/strong><\/p>\n<p style=\"text-align: justify\">Management of the condition revolves around reducing intraocular pressure (IOP) through the use of current drug classes, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. Despite these treatments, some patients do not experience the desired improvement in their condition. They may still face optic nerve damage even when their IOP levels are within the normal range. In addition to pharmacological treatments, alternatives such as incisional surgery, laser surgery, and medications are also considered.<\/p>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Glaucoma Drugs Uptake<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li><strong><em>NCX 470<\/em><\/strong>&nbsp;is a novel NO-donating bimatoprost eye drop, which is a prostaglandin analog. The drug is currently being developed by Nicox Ophthalmics and is in Phase III of clinical development. It is being developed for the treatment of open-angle glaucoma or ocular hypertension in the US. NCX 470 is designed to release bimatoprost and NO following instillation into the eye.<\/li>\n<li><strong><em>PDP-716<\/em><\/strong>&nbsp;is a novel, once-a-day formulation of brimonidine developed using SPARC&rsquo;s TearAct technology for the treatment of glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine, one of the most commonly used treatments for glaucoma and ocular hypertension.<\/li>\n<li><strong><em>STN-1012600<\/em><\/strong>&nbsp;is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, STN-1012600 is expected to give new therapeutic options for treating glaucoma.<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Glaucoma Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify\">The report&#8217;s outlook on the Glaucoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glaucoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glaucoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion\/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glaucoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Major Glaucoma Companies<\/strong><\/p>\n<p style=\"text-align: justify\">Several Glaucoma Companies working in the market include&nbsp;<strong><em>Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck &amp; Co, Aerie Pharmaceuticals, Ube Industries<\/em><\/strong>, and others.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Unlock insights into the Glaucoma Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Glaucoma Market Forecast. Click here @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Glaucoma Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Scope of the Glaucoma Market Research Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Coverage- 7MM<\/li>\n<li>Glaucoma Companies- Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck &amp; Co, Aerie Pharmaceuticals, Ube Industries, and others.<\/li>\n<li>Glaucoma Therapies- NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost\/ DE-126\/ ONO-9054\/ STN-1012600, Catioprost\/ DE-130A\/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.<\/li>\n<li>Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers<\/li>\n<li>Glaucoma Market Access and Reimbursement, Unmet Needs and Future Perspectives<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Gain a strategic edge in the Glaucoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Glaucoma Market Forecast. Click here to lead in advancements @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glaucoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Glaucoma Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify\">1. Key Insights<\/p>\n<p style=\"text-align: justify\">2. Report Introduction<\/p>\n<p style=\"text-align: justify\">3. Country-wise Glaucoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify\">4. Glaucoma Market Overview by Class<\/p>\n<p style=\"text-align: justify\">5. Methodology of Glaucoma Epidemiology and Market<\/p>\n<p style=\"text-align: justify\">6. Executive Summary of Glaucoma<\/p>\n<p style=\"text-align: justify\">7. Key Events<\/p>\n<p style=\"text-align: justify\">8. Disease Background and Overview of Glaucoma<\/p>\n<p style=\"text-align: justify\">9. Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify\">10. Patient Journey<\/p>\n<p style=\"text-align: justify\">11.&nbsp;Glaucoma&nbsp;Marketed Therapies<\/p>\n<p style=\"text-align: justify\">12.&nbsp;Glaucoma&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify\">13. Glaucoma Market Analysis<\/p>\n<p style=\"text-align: justify\">14. Key Opinion Leaders&rsquo; Views<\/p>\n<p style=\"text-align: justify\">15.&nbsp;Glaucoma&nbsp;SWOT Analysis<\/p>\n<p style=\"text-align: justify\">16.&nbsp;Glaucoma&nbsp;Unmet needs<\/p>\n<p style=\"text-align: justify\">17.&nbsp;Glaucoma&nbsp;Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify\">18. Appendix<\/p>\n<p style=\"text-align: justify\">19. Report Methodology<\/p>\n<p style=\"text-align: justify\">20. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify\">21. Disclaimer&nbsp;<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p class=\"caps\"><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=glaucoma-drugs-market-size-2034-allergan-sun-pharma-advanced-research-company-limited-santen-pharmaceutical-co-ltd-dwestern-therapeutics-institute-dwti-kowa-ltd-alcon\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=glaucoma-drugs-market-size-2034-allergan-sun-pharma-advanced-research-company-limited-santen-pharmaceutical-co-ltd-dwestern-therapeutics-institute-dwti-kowa-ltd-alcon\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s&nbsp;&ldquo;Glaucoma Market Insights, Epidemiology and Market Forecast &ndash; 2034&rdquo;&nbsp;report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/501548"}],"collection":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/comments?post=501548"}],"version-history":[{"count":0,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/501548\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/media?parent=501548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/categories?post=501548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/tags?post=501548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}